Sirolimus resolves the percentage of DNTs to a normal range in ALPS patients. (A) Patients with ALPS included in the clinical trial. (B) Patients with ALPS included in a biology study, not enrolled in the clinical trial. For both panels, the dotted line represents the normal threshold of circulating DNTs (<2.6%).